Amendment: SEC Form 20-F/A filed by Brazil Potash Corp.
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
M5R 1J2 Tel: +1 (416) 309-2963 | ||
(Jurisdiction of incorporation or organization) |
(Address of principal executive offices) |
Title of each class to be registered |
Trading Symbol(s) |
Name of each exchange on which each class is to be registered | ||
Large accelerated filer | ☐ | Accelerated filer | ☐ | ☐ | ||||||
Emerging Growth Company |
U.S. GAAP ☐ | |
Other ☐ | ||||||
by the International Accounting Standards Board | ☒ |
2024 |
2023 (1) |
|||||||
(USD in thousands) |
||||||||
Fees for audit services (2) |
173.7 |
120.6 |
||||||
Fees for tax compliance, tax advise, and tax planning (2) |
4.2 |
4.4 |
||||||
Fees for any other services not included above (3) |
88.2 |
18.6 |
||||||
Total |
266.1 |
143.6 |
||||||
(1) |
Represents the fees that were paid in Canadian dollars, as converted into U.S. dollars based on the currency exchange rate between the Canadian dollar and the U.S. dollar on December 31, 2024 and 2023, respectively. |
(2) |
Fees related to the years ended December 31, 2024 and 2023 include professional services rendered in connection with the audit of our annual consolidated financial statements and the review of our consolidated interim financial statements, statutory audits of the Company and its subsidiaries, issuance of consents and assistance with review of documents filed with the SEC. |
(3) |
Fees related to the IPO. |
• |
the same disclosure and reporting requirements as a U.S. domestic issuer under the Exchange Act, including the requirements to prepare and issue quarterly reports on Form 10-Q or to file current reports on Form 8-K upon the occurrence of specified significant events; |
• |
the proxy rules applicable to U.S. domestic issuers under Section 14 of the Exchange Act; |
• |
the insider reporting and short-swing profit rules applicable to U.S. domestic issuers under Section 16 of the Exchange Act, which means that our shareholders may not know on as timely a basis when our directors, executives, and principal shareholders purchase or sell our Common Shares; or |
• |
Regulation FD, which regulates selective disclosures of material information by issuers. |
PART III
ITEM 19. EXHIBITS.
Exhibit No. |
Exhibit Description | |
101.INS* | Inline XBRL Instance Document | |
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
101.PRE* | Inline XBRL Taxonomy Presentation Linkbase Document | |
101.CAL* | Inline XBRL Taxonomy Calculation Linkbase Document | |
101.LAB* | Inline XBRL Taxonomy Label Linkbase Document | |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
104* | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
* | Filed herewith. |
SIGNATURES
The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Amendment No. 1 to Annual Report on Form 20-F on its behalf.
BRAZIL POTASH CORP. | ||||||
Date: April 9, 2025 | By: | /s/ Matthew Simpson | ||||
Matthew Simpson | ||||||
Chief Executive Officer |
F-2 | ||
F-3 | ||
F-4 | ||
F-5 | ||
F-6 | ||
F-7 – F-39 |


Suite 900, 50 Burnhamthorpe Road W, Mississauga ON, L5B 3C2 | T: 416.626.6000 F: 416.626.8650 |

As at: |
December 31, 2024 |
December 31, 2023 |
||||||
ASSETS |
||||||||
Current |
||||||||
Cash and cash equivalents (Note 6) |
$ |
$ | ||||||
Amounts receivable (Note 7) |
||||||||
Prepaid expenses (Note 8) |
||||||||
Total current assets |
||||||||
Non-current |
||||||||
Property and equipment (Note 9) |
||||||||
Right of use asset (Note 10) |
||||||||
Exploration and evaluation assets (Note 11) |
||||||||
Total assets |
$ |
$ | ||||||
LIABILITIES |
||||||||
Current |
||||||||
Trade payables and accrued liabilities (Notes 12, 19) |
$ |
$ | ||||||
Current portion of lease liability (Note 10) |
||||||||
Total current liabilities |
||||||||
Non-current |
||||||||
Lease liability (Note 10) |
||||||||
Warrant liability (Note 15) |
||||||||
Deferred income tax liability (Note 5) |
||||||||
Total liabilities |
||||||||
Equity |
||||||||
Share capital (Note 13) |
||||||||
Share-based payments reserve (Note 14) |
||||||||
Warrants reserve (Note 15) |
||||||||
Accumulated other comprehensive loss |
( |
) |
( |
) | ||||
Deficit |
( |
) |
( |
) | ||||
Total equity |
||||||||
Total liabilities and equity |
$ |
$ | ||||||
Year ended December 31, 2024 |
Year ended December 31, 2023 |
Year ended December 31, 2022 |
||||||||||
Expenses |
||||||||||||
Consulting and management fees (Note 19) |
$ |
$ | $ | |||||||||
Professional fees |
||||||||||||
Share-based compensation (Notes 14, 19) |
||||||||||||
Travel expenses (Note 19) |
||||||||||||
General office expenses |
||||||||||||
Foreign exchange (gain) |
( |
) |
( |
) | ||||||||
Communications and promotions |
||||||||||||
Operating Loss |
||||||||||||
Finance income |
( |
) |
( |
) | ( |
) | ||||||
Change in fair value of warrant liability (Note 15) |
( |
) |
— | — | ||||||||
Loss for the year before income taxes |
||||||||||||
Deferred income tax provision (Note 5) |
||||||||||||
Loss for the year after income taxes |
||||||||||||
Other comprehensive loss (income): |
||||||||||||
Items that subsequently may be reclassified into net income: |
||||||||||||
Foreign currency translation |
( |
) | ( |
) | ||||||||
Total comprehensive loss for the year |
$ |
$ | $ | |||||||||
Basic and diluted loss per share (Note 16) |
$ |
$ | $ | |||||||||
Weighted average number of common shares outstanding - basic and diluted |
||||||||||||
Common Shares | Warrants | Share-based payments reserve |
Accumulated Other Comprehensive Income (Loss) |
Accumulated Deficit |
Shareholders’ Equity |
|||||||||||||||||||||||
# |
$ |
$ |
$ |
$ |
$ |
$ |
||||||||||||||||||||||
Balance, December 31, 2021 |
( |
) | ( |
) | ||||||||||||||||||||||||
Deferred share units |
— | — | — | — | — | |||||||||||||||||||||||
Deferred share units exercised (Notes 13 and 14(b)) |
— | ( |
) | — | — | — | ||||||||||||||||||||||
Reg A Offering (Note 13) |
— | — | — | — | ||||||||||||||||||||||||
Share issuance costs (Note 13) |
— | ( |
) | — | — | — | — | ( |
) | |||||||||||||||||||
Option extension (Note 14(a)) |
— | — | — | — | ( |
) | ||||||||||||||||||||||
Option grant (Note 14(a)) |
— | — | — | — | — | |||||||||||||||||||||||
Option expiry (Note 14(a)) |
— | — | — | ( |
) | — | — | |||||||||||||||||||||
Loss and comprehensive income for the year |
— | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||
Balance, December 31, 2022 |
( |
) | ( |
) | ||||||||||||||||||||||||
Deferred share units |
— | — | — | — | — | |||||||||||||||||||||||
Deferred share units exercised (Notes 13 and 14(b)) |
— | ( |
) | — | — | — | ||||||||||||||||||||||
Option vesting |
— | — | — | — | — | |||||||||||||||||||||||
Option exercise (Note 14(a) |
— | ( |
) | — | — | |||||||||||||||||||||||
Option expiry (Note 14(a)) |
— | — | — | ( |
) | — | — | |||||||||||||||||||||
Loss and comprehensive income for the year |
— | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||
Balance, December 31, 2023 |
( |
) | ( |
) | ||||||||||||||||||||||||
Initial Public Offering (Note 13(b)) |
— | — | — | — | ||||||||||||||||||||||||
Share issuance costs (Note 13(b)) |
— | ( |
) | — | — | — | — | ( |
) | |||||||||||||||||||
Deferred share units (Note 14(b)) |
— | — | — | — | — | |||||||||||||||||||||||
Deferred share units exercised (Notes 13 and 14(b)) |
— | ( |
) | — | — | — | ||||||||||||||||||||||
Restricted share units (Note 14(c)) |
— | — | — | — | — | |||||||||||||||||||||||
Restricted share units exercised (Note 14(c)) |
— | ( |
) | — | ||||||||||||||||||||||||
Option vesting (Note 14(a)) |
— | — | — | — | — | |||||||||||||||||||||||
Option exercise (Note 14(a) |
— | ( |
) | — | — | |||||||||||||||||||||||
Option expiry (Note 14(a)) |
— | — | — | ( |
) | — | — | |||||||||||||||||||||
Warrants issued (Note 15) |
— | — | — | — | — | |||||||||||||||||||||||
Warrant exercise (Note 15) |
( |
) | — | — | — | |||||||||||||||||||||||
Loss and comprehensive loss for the year |
— | — | — | — | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
Balance, December 31, 2024 |
( |
) | ( |
) | ||||||||||||||||||||||||
Year ended December 31, 2024 |
Year ended December 31, 2023 |
Year ended December 31, 2022 |
||||||||||
CASH FLOWS FROM |
||||||||||||
OPERATING ACTIVITIES |
||||||||||||
Loss for the year |
$ |
( |
) |
$ | ( |
) | $ | ( |
) | |||
Adjustment for: |
||||||||||||
Finance income |
( |
) |
( |
) | ( |
) | ||||||
Share-based compensation |
||||||||||||
Change in fair value of warrant liability |
( |
) |
||||||||||
Deferred income tax provision |
||||||||||||
( |
) |
( |
) | ( |
) | |||||||
Change in amounts receivable |
( |
) |
||||||||||
Change in prepaid expenses |
( |
) |
( |
) | ||||||||
Change in trade payables and accrued liabilities |
( |
) | ||||||||||
Net cash used in operating activities |
( |
) |
( |
) | ( |
) | ||||||
CASH FLOWS FROM |
||||||||||||
FINANCING ACTIVITIES |
||||||||||||
Initial Public Offering, net of issue costs |
||||||||||||
Proceeds from Reg A offering, net of share issue costs |
||||||||||||
Option exercise |
||||||||||||
Warrant exercise |
||||||||||||
Principal reduction in lease liability |
( |
) |
||||||||||
Net cash from financing activities |
||||||||||||
CASH FLOWS FROM |
||||||||||||
INVESTING ACTIVITIES |
||||||||||||
Acquisition of property and equipment |
( |
) |
( |
) | ( |
) | ||||||
Exploration and evaluation assets |
( |
) |
( |
) | ( |
) | ||||||
Finance income |
||||||||||||
Net cash used in investing activities |
( |
) |
( |
) | ( |
) | ||||||
Effect of exchange rate changes on cash and cash equivalents |
( |
) |
( |
) | ||||||||
NET DECREASE IN CASH AND CASH EQUIVALENTS |
( |
) | ( |
) | ||||||||
CASH AND CASH EQUIVALENTS, beginning of year |
||||||||||||
CASH AND CASH EQUIVALENTS, end of year |
$ |
$ | $ | |||||||||
SUPPLEMENTAL INFORMATION: |
||||||||||||
Depreciation of assets capitalized to exploration and evaluation assets |
$ |
$ | $ | |||||||||
Share-based compensation included in exploration and evaluation assets |
||||||||||||
Value of broker warrants issued |
||||||||||||
Right of use asset and lease liability at inception |
||||||||||||
Lease finance interest capitalized to exploration and evaluation assets |
||||||||||||
Change in receivable on Reg A offering |
( |
) |
1. |
Reporting entity and going concern |
% Ownership |
||||||||||||||||
Country of incorporation |
December 31, 2024 |
December 31, 2023 |
December 31, 2022 |
|||||||||||||
Potassio do Brasil Ltda. |
% |
% | % |
1. |
Reporting entity and going concern (continued) |
2. |
Basis of preparation |
a) | Statement of compliance: |
b) | Basis of measurement: |
c) | Functional and presentation currency: |
3. |
Material accounting policies |
a) | Basis of consolidation |
3. |
Material accounting policies (continued) |
b) | Foreign currency transactions |
c) | Cash and cash equivalents |
d) | Property and equipment |
(i) | Recognition and measurement |
(ii) | Depreciation |
• | Vehicle | |||
• | Office equipment | |||
• | Furniture and fixtures |
3. |
Material accounting policies (continued) |
e) | Exploration and evaluation assets |
(i) | the period for which the Company has a right to explore in the specific area has expired or is expected to expire; |
(ii) | the exploration and evaluation has not led to the discovery of economic reserves; |
(iii) | the development of the reserves is not economically or commercially viable; and |
(iii) | the exploration is located in an area that has become politically unstable. |
3. |
Material accounting policies (continued) |
f) | Leases and Right-of-Use |
g) | Financial instruments |
g) | Financial instruments (continued) |
h) | Provisions |
i) | Income taxes |
3. |
Material accounting policies (continued) |
i) | Income taxes (continued) |
j) | Share-based payments |
3. |
Material accounting policies (continued) |
4. |
Use of estimates and judgments |
4. |
Use of estimates and judgments (continued) |
(i) | Impairment of exploration and evaluation expenditures: |
(ii) | Contingencies: |
(iii) | Fair value of stock-based compensation and warrants: |
(iv) | Going concern: |
(v) | Reclassification from exploration and evaluation to development costs: |
4. |
Use of estimates and judgments (continued) |
(vi) | Leases: |
5. |
Income taxes |
December 31, 2024 |
December 31, 2023 |
December 31, 2022 |
||||||||||
Loss before income tax |
$ |
( |
) |
$ | ( |
) | $ | ( |
) | |||
Canadian Statutory Tax Rate |
% |
% | % | |||||||||
Expected tax recovery |
$ |
( |
) |
$ | ( |
) | $ | ( |
) | |||
Share-based compensation |
||||||||||||
Foreign tax rate deferential |
||||||||||||
Change in tax benefit not recognized |
||||||||||||
Total |
$ |
$ | $ | |||||||||
December 31, 2024 |
December 31, 2023 |
December 31, 2022 |
||||||||||
Current tax expense |
$ | $ | $ | |||||||||
Deferred tax expense |
||||||||||||
Total |
$ |
$ | $ | |||||||||
December 31, 2024 |
December 31, 2023 |
December 31, 2022 |
||||||||||
Balance, beginning of year |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
Deferred income tax expense |
( |
) | ( |
) | ( |
) | ||||||
Foreign currency translation |
( |
) | ( |
) | ||||||||
Balance, end of year |
$ |
( |
) |
$ | ( |
) | $ | ( |
) | |||
5. |
Income taxes (continued) |
December 31, 2024 |
December 31, 2023 |
December 31, 2022 |
||||||||||
Exploration and evaluation assets |
$ |
( |
) |
$ | ( |
) | $ | ( |
) | |||
Loss carryforwards |
||||||||||||
Deferred tax liabilities, net |
$ |
( |
) |
$ | ( |
) | $ | ( |
) | |||
Canada |
December 31, 2024 |
December 31, 2023 |
||||||
Non-capital losses |
$ | $ | ||||||
Deductible temporary differences |
$ | $ | ||||||
Brazil |
December 31, 2024 |
December 31, 2023 |
||||||
Non-capital losses |
$ | $ |
5. |
Income taxes (continued) |
Year of Expiry |
Amount | |||
2044 |
$ | |||
2043 |
||||
2042 |
||||
2041 |
||||
2040 |
||||
2039 |
||||
2038 |
||||
2037 |
||||
2036 |
||||
2035 |
||||
2034 |
||||
2033 |
||||
2032 |
||||
2031 |
||||
2030 |
||||
2029 |
||||
$ |
||||
6. |
Cash and cash equivalents |
December 31, 2024 |
December 31, 2023 |
|||||||
Cash at banks |
$ |
$ | ||||||
Short-term deposits |
||||||||
$ |
$ | |||||||
7. |
Amounts receivable |
December 31, 2024 |
December 31, 2023 |
|||||||
HST |
$ |
$ | ||||||
Other receivables |
||||||||
Total amounts receivable |
$ |
$ | ||||||
8. |
Prepaid expenses |
December 31, 2024 |
December 31, 2023 |
|||||||
Prepaid insurance |
$ |
$ | ||||||
Other |
||||||||
$ |
$ | |||||||
9. |
Property and equipment |
Vehicles |
Office equipment |
Furniture and fixtures |
Land |
Total |
||||||||||||||||
Cost: |
||||||||||||||||||||
At January 1, 2024 |
$ | $ | $ | $ | $ | |||||||||||||||
Additions |
||||||||||||||||||||
Effect of foreign exchange |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||
At December 31, 2024 |
$ | $ | $ | $ | $ | |||||||||||||||
Depreciation: |
||||||||||||||||||||
At January 1, 2024 |
$ | $ | $ | $ | $ | |||||||||||||||
Effect of foreign exchange |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Depreciation charge for the year |
||||||||||||||||||||
At December 31, 2024 |
$ | $ | $ | $ | $ | |||||||||||||||
Net book value: |
||||||||||||||||||||
At December 31, 2024 |
$ |
$ |
$ |
$ |
$ |
|||||||||||||||
At January 1, 2024 |
$ | $ | $ | $ | $ | |||||||||||||||
Cost: |
||||||||||||||||||||
At January 1, 2023 |
$ | $ | $ | $ | $ | |||||||||||||||
Additions |
||||||||||||||||||||
Effect of foreign exchange |
||||||||||||||||||||
At December 31, 2023 |
$ | $ | $ | $ | $ | |||||||||||||||
Depreciation: |
||||||||||||||||||||
At January 1, 2023 |
$ | $ | $ | $ | $ | |||||||||||||||
Effect of foreign exchange |
||||||||||||||||||||
Depreciation charge for the year |
||||||||||||||||||||
At December 31, 2023 |
$ | $ | $ | $ | $ | |||||||||||||||
Net book value: |
||||||||||||||||||||
At December 31, 2023 |
$ |
$ |
$ |
$ |
$ |
|||||||||||||||
At January 1, 2023 |
$ | $ | $ | $ | $ |
9. |
Property and equipment (continued) |
Vehicles |
Office equipment |
Furniture and fixtures |
Land |
Total |
||||||||||||||||
Cost: |
||||||||||||||||||||
At January 1, 2022 |
$ | $ | $ | $ | $ | |||||||||||||||
Additions |
||||||||||||||||||||
Effect of foreign exchange |
||||||||||||||||||||
At December 31, 2022 |
$ | $ | $ | $ | $ | |||||||||||||||
Depreciation: |
||||||||||||||||||||
At January 1, 2022 |
$ | $ | $ | $ | $ | |||||||||||||||
Effect of foreign exchange |
||||||||||||||||||||
Depreciation charge for the year |
||||||||||||||||||||
At December 31, 2022 |
$ | $ | $ | $ | $ | |||||||||||||||
Net book value: |
||||||||||||||||||||
At December 31, 2022 |
$ |
$ |
$ |
$ |
$ |
|||||||||||||||
At January 1, 2022 |
$ | $ | $ | $ | $ |
10. |
Leases |
Cost |
Amortization |
Balance |
||||||||||
Balance, December 31, 2023 |
$ | $ | $ | |||||||||
Additions |
( |
) | ||||||||||
Effect of Foreign Exchange |
( |
) | ( |
) | ||||||||
Balance, December 31, 2024 |
$ |
$ |
( |
) |
||||||||
10. |
Leases (continued) |
December 31, 2024 |
||||
Balance, beginning of year |
$ |
|||
Acquisition of lease |
||||
Cash outflows |
( |
) | ||
Finance costs |
||||
Effect of foreign exchange |
( |
) | ||
Balance, end of year |
$ |
|||
December 31, 2024 |
Lease Liability - current |
$ |
|||
Lease Liability - non-current |
||||
$ |
11. |
Exploration and evaluation assets |
December 31, 2024 |
December 31, 2023 | |||||||
Balance, beginning of year |
$ |
$ | ||||||
Additions: |
||||||||
Mineral rights and land fees |
||||||||
Site operations, environmental, consulting and technical costs |
||||||||
Share-based compensation (Note 14) |
||||||||
Proceeds from royalty option agreement* |
( |
) |
||||||
Effect of foreign exchange |
( |
) |
||||||
Balance, end of year |
$ |
$ | ||||||
* | On November 1, 2024, the Company and its Subsidiary entered into an option agreement (see Note 20) and received $ |
12. |
Trade payables and accrued liabilities |
December 31, 2024 |
December 31, 2023 |
|||||||
Trade payables |
$ |
$ | ||||||
Accruals |
||||||||
Total trade payables and accrued liabilities |
$ |
$ | ||||||
13. |
Share capital |
(a) | Authorized |
(b) | Issued |
December 31, 2024 |
December 31, 2023 | December 31, 2022 | ||||||||||||||||||||||
Number of shares |
Stated Value $ |
Number of shares |
Stated Value $ |
Number of shares |
Stated Value $ |
|||||||||||||||||||
Common shares |
||||||||||||||||||||||||
Balance, beginning of year |
||||||||||||||||||||||||
Initial public offering, net of issuance costs |
||||||||||||||||||||||||
Reg A offering, net of issue costs |
||||||||||||||||||||||||
DSU exercise (Note 14) |
||||||||||||||||||||||||
RSU exercise (Note 14) |
||||||||||||||||||||||||
Option exercise (Note 14) |
||||||||||||||||||||||||
Warrant exercise (Note 15) |
||||||||||||||||||||||||
Balance, end of year |
||||||||||||||||||||||||
13. |
Share capital (continued) |
(b) | Issued |
14. |
Share-based payments |
December 31, 2024 |
December 31, 2023 | December 31, 2022 | ||||||||||
Balance, beginning of the year |
$ |
$ | $ | |||||||||
Vesting and forfeiture of options |
||||||||||||
Vesting and forfeiture of DSUs |
||||||||||||
Vesting of RSUs |
||||||||||||
Option extension |
||||||||||||
DSU exercise |
( |
) |
( |
) | ( |
) | ||||||
RSU exercise |
( |
) |
||||||||||
Option exercise |
( |
) |
( |
) | ||||||||
Expired options |
( |
) |
( |
) | ( |
) | ||||||
Balance, end of the year |
$ |
$ | $ | |||||||||
(a) | Option plan: |
• | the number of options granted in a twelve-month period to any one consultant exceeding |
• | the aggregate number of options granted in a twelve-month period to any one optionee exceeding |
• | the number of options granted in a twelve-month period to employees and management company employees undertaking investor relations activities exceeding in aggregate |
14. |
Share-based payments (continued) |
(a) | Option plan (continued): |
December 31, 2024 |
December 31, 2023 | December 31, 2022 | ||||||||||||||||||||||
Number of options |
Weighted average exercise price |
Number of options |
Weighted average exercise price |
Number of options |
Weighted average exercise price |
|||||||||||||||||||
Balance, beginning of year |
$ |
$ | $ | |||||||||||||||||||||
Granted |
||||||||||||||||||||||||
Extended |
||||||||||||||||||||||||
Exercised |
( |
) |
( |
) | ||||||||||||||||||||
Expired |
( |
) |
||||||||||||||||||||||
Cancelled |
( |
) | ( |
) | ||||||||||||||||||||
Balance, end of year |
$ |
$ | $ | |||||||||||||||||||||
14. |
Share-based payments (continued) |
(a) | Option plan (continued): |
Date of expiry |
Options outstanding |
Options exercisable |
Exercise price |
|||||||||
July 20, 2025 |
$ | |||||||||||
July 20, 2025 |
$ | |||||||||||
January 20, 2027 |
$ | |||||||||||
May 11, 2028 |
$ | |||||||||||
(b) | Deferred share units plan (“DSU”): |
14. |
Share-based payments (continued) |
(b) | Deferred share units plan (“DSU”) (continued): |
Year ended December 31, 2024 |
Year ended December 31, 2023 |
Year ended December 31, 2022 |
||||||||||
Balance, beginning of year |
||||||||||||
Forfeit |
( |
) |
||||||||||
Cancelled |
( |
) | ||||||||||
Exercised |
( |
) |
( |
) | ( |
) | ||||||
Granted |
||||||||||||
Balance, end of year |
||||||||||||
(i) | As to one-third of the DSUs, vesting shall occur immediately; |
(ii) | As to the second one-third, upon the later of (a) completion by the Company of a pre-feasibility study or feasibility study; and (b) receipt by the Company of the preliminary license for the project; and |
(iii) | As to the final one third of the DSUs, upon the Company completing arrangements for project construction financing, as detailed in the pre-feasibility study or feasibility study for the project. |
14. |
Share-based payments (continued) |
(b) | Deferred share units plan (“DSU”) (continued): |
14. |
Share-based payments (continued) |
(b) | Deferred share units plan (“DSU”) (continued): |
(c) | Restricted share units plan (“RSU”): |
Year ended December 31, 2024 |
Years ended December 31, 2023 and 2022 |
|||||||
Balance, beginning of year |
||||||||
Granted |
||||||||
Exercised |
( |
) |
||||||
Forfeit |
||||||||
Balance, end of year |
||||||||
14. |
Share-based payments (continued) |
14. |
Share-based payments (continued) |
(c) | Restricted share units plan (“RSU”) (continued): |
15. |
Warrants and warrant liability |
Number of warrants |
Exercise price |
Expiry Date | ||||||
$ | ||||||||
November 27, 2025 | * | |||||||
November 26, 2026 | ||||||||
* | On September 11, 2009, the Company issued |
15. |
Warrants and warrant liability (continued) |
Year ended December 31, 2024 |
Years ended December 31, 2023 and 2022 |
|||||||||||||||||||||||
Number of warrants |
Weighted average exercise price |
Fair value |
Number of warrants |
Weighted average exercise price |
Grant date fair value |
|||||||||||||||||||
Balance, beginning of year |
$ |
$ |
$ | $ | ||||||||||||||||||||
Granted |
||||||||||||||||||||||||
Change in fair value |
( |
) |
||||||||||||||||||||||
Balance, end of year |
$ |
$ |
$ | $ | ||||||||||||||||||||
15. |
Warrants and warrant liability (continued) |
Year ended December 31, 2024 |
Years ended December 31, 2023 and 2022 |
|||||||||||||||||||||||
Number of warrants |
Weighted average exercise price |
Grant date fair value |
Number of warrants |
Weighted average exercise price |
Grant date fair value |
|||||||||||||||||||
Balance, beginning of year |
$ |
$ |
$ | $ | ||||||||||||||||||||
Granted |
$ |
|||||||||||||||||||||||
Exercised |
( |
) |
( |
) |
||||||||||||||||||||
Balance, end of year |
$ |
$ |
$ | $ | ||||||||||||||||||||
16. |
Loss per share |
17. |
Financial Risk Management Objectives and Policies |
17. |
Financial Risk Management Objectives and Policies (continued) |
(a) | Interest rate risk |
(b) | Foreign currency risk |
Average rate |
Closing rate |
|||||||
CAD |
||||||||
BRL |
17. |
Financial Risk Management Objectives and Policies (continued) |
(b) | Foreign currency risk |
(c) | Capital management |
18. |
Financial Instruments |
Financial instrument classification |
Carrying amount |
Fair value |
||||||||||
As at December 31, 2024 |
$ |
$ |
||||||||||
Financial assets: |
||||||||||||
Cash and cash equivalents |
FVPL | |||||||||||
Amounts receivable |
Amortized cost | |||||||||||
Financial liabilities: |
||||||||||||
Trade payables and accrued liabilities |
Amortized cost | |||||||||||
Lease liability |
Amortized cost | |||||||||||
As at December 31, 2023 |
$ |
$ |
||||||||||
Financial assets: |
||||||||||||
Cash and cash equivalents |
FVPL | |||||||||||
Amounts receivable |
Amortized cost | |||||||||||
Financial liabilities: |
||||||||||||
Trade payables and accrued liabilities |
Amortized cost |
18. |
Financial Instruments (continued) |
19. |
Related Party Disclosures |
(a) | Key management personnel compensation |
Year ended December 31, 2024 |
Year ended December 31, 2023 |
Year ended December 31, 2022 |
||||||||||
Directors & officers compensation |
$ |
$ | $ | |||||||||
Share-based payments |
||||||||||||
$ |
$ | $ | ||||||||||
(b) | Transactions with other related parties |
19. |
Related Party Disclosures (continued) |
20. |
Commitments and contingencies |
21. |
Subsequent events |